The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for LifeSpan Biosciences sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights LifeSpan Biosciences Inc, United States Revenue

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

LifeSpan Biosciences Inc (LSBio) is an immuno-histochemistry antibody company. The company offers antibodies, ELISA and assay kits, proteins, biochemical, and immunohistochemistry (IHC) reagent. In addition, the company also provides immunohistochemistry services and TCR screening services. Its research areas include breast cancer IHC, colorectal cancer IHC, lung cancer IHC and prostate cancer IHC. LSBio’s proteins comprise recombinant proteins, native proteins, over-expression lysates, cell and tissue lysates, bio-active proteins and animal-free proteins, among others. The company markets its products through a network of distributors in Australia, Albania, India, Ghana, Greece, Greenland, Hong Kong, Indonesia, Iceland and Hungary, among others. It also sells its products through online. LSBio is headquartered in Seattle, Washington, the US. Key subsidiaries of LifeSpan Biosciences include Everest Biotech, Nordic-MUbio, Kerafast and Absolute Antibody.

The key metrics of LifeSpan Biosciences related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:

As LifeSpan Biosciences is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as LifeSpan Biosciences.

For a detailed understanding of the performance of LifeSpan Biosciences, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s revenue report leverages GlobalData’s SKU tracker, which contains real-world, purchasing data from the US healthcare institutions.